In the BioHarmony Drug Report Database

"Preview" Icon

Idecabtagene vicleucel

Abecma (idecabtagene vicleucel) is a gene pharmaceutical. Idecabtagene vicleucel was first approved as Abecma on 2021-03-03. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat blood protein disorders, cardiovascular diseases, hematologic diseases, hemic and lymphatic diseases, and hemorrhagic disorders amongst others.

 

Trade Name

 

Abecma
 

Common Name

 

idecabtagene vicleucel
 

ChEMBL ID

 

CHEMBL4298199
 

Indication

 

blood protein disorders, cardiovascular diseases, hematologic diseases, hemic and lymphatic diseases, hemorrhagic disorders, hemostatic disorders, immune system diseases, immunoproliferative disorders, infectious mononucleosis, lymphoproliferative disorders, multiple myeloma, neoplasms, paraproteinemias, plasma cell neoplasms, vascular diseases
 

Drug Class

 

Antineoplastic

Image (chem structure or protein)

Idecabtagene vicleucel structure rendering